Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 1 - 10 of about 148   

Articles published

GSK 1,722.00 +39.00 (2.32%)
price chart
Jefferies Group Brokers Boost Earnings Estimates for GlaxoSmithKline PLC (GSK)
GlaxoSmithKline PLC (NYSE:GSK) - Analysts at Jefferies Group raised their FY2021 earnings per share estimates for GlaxoSmithKline PLC in a report released on Friday. Jefferies Group analyst J. Holford now expects that the pharmaceutical company will ...
GlaxoSmithKline plc (GSK) loses confidence of 52 hedge fund managers  Post Analyst
GlaxoSmithKline PLC (GSK) Given Daily Media Impact Rating of 0.24  The Cerbat Gem
Market Risers: Fresnillo Plc, GlaxoSmithKline plc, Provident Financial plc ...
The trading price for Fresnillo Plc EPIC code: LON:FRES has stepped up 1.29% or 20 points throughout today's trading session so far.
GlaxoSmithKline makes submissions for key HIV single-tablet treatment to both ...
GlaxoSmithKline plc (LON:GSK) and ViiV Healthcare have made regulatory submissions to both the European Medicines Agency and the US Food and Drug Administration for use of a single-tablet, two-drug regimen for the maintenance treatment of HIV-1 ...
GlaxoSmithKline Shares Boosted By Renewed Push In HIV Treatment  TheStreet.com
TOP NEWS: GlaxoSmithKline Submits Applications For HIV Drugs  London South East (registration) (blog)
GSK's new CEO aims to divest sports nutrition brand: sources
LONDON GlaxoSmithKline Plc's new Chief Executive Officer Emma Walmsley is shaking up the British drugmaker's portfolio of smaller products with plans to divest its MaxiNutrition sports nutrition brand, two people familiar with the matter said on Thursday.
GlaxoSmithkline: Long-term value emerging, says broker
Long-term value is “emerging” at GlaxoSmithKline plc (LON:GSK), according to the German bank Berenberg, which upgraded the stock.
Opus Capital Group LLC Holds Position in GlaxoSmithKline plc (GSK)  BNB Daily (blog)
GlaxoSmithKline plc (GSK) Upgraded to Hold at Zacks Investment Research  Sports Perspectives
GSK Wins $235 Million From Teva in Coreg Patent Trial
(Reuters) - A U.S. jury has ordered Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million (�185 million) for infringing a patent covering its blood pressure drug Coreg, court documents showed.
PRESS: GlaxoSmithKline Awarded USD235 Million In US Generic Drug Case  London South East (registration) (blog)
GlaxoSmithKline plc (ADR) (NYSE:GSK) To Receive $235M From Teva ...  The Momentous News
Today Liberum Capital Reaffirms a “Buy” Rating on GlaxoSmithKline PLC (LON:GSK ...
In a note revealed to investors this morning, Liberum Capital restate their “Buy” rating on GlaxoSmithKline PLC (LON:GSK) shares.
Analyst at Shore Capital Keeps The GlaxoSmithKline PLC (LON:GSK) Hold Rating ...  KL Daily
MUFG Americas Holdings Corp Cuts Stake in GlaxoSmithKline PLC (GSK)
GlaxoSmithKline PLC logo MUFG Americas Holdings Corp decreased its stake in shares of GlaxoSmithKline PLC (NYSE:GSK) by 10.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC).
Analysts Upgrade/Downgrade Activity of GlaxoSmithKline plc (GSK)  FactsReporter
Trust Co. of Vermont Raises Stake in GlaxoSmithKline PLC (GSK)  Sports Perspectives
Inspecting more closely technicals of GlaxoSmithKline plc (GSK)
With all other things going on, GlaxoSmithKline plc (NYSE:GSK) has been on a run - rising 3.17 percent in just three months.
Did GlaxoSmithKline plc (LSE:GSK) Create Value For Shareholders?
While GlaxoSmithKline plc's (LSE:GSK) 31.9% ROE was above the industry average of 20.6%, the role of leverage must also be considered.
GlaxoSmithKline plc (GSK) Receives Equal weight Rating from Barclays PLC  Sports Perspectives
GlaxoSmithKline plc (GSK) PT Set at GBX 1700 by Morgan Stanley  The Cerbat Gem